S. Bhargava, Ranjani Panda, Asma M. Azam, J. Sheppard
{"title":"A review of dry eye disease therapies: exploring the qualities of varenicline solution nasal spray","authors":"S. Bhargava, Ranjani Panda, Asma M. Azam, J. Sheppard","doi":"10.1080/17469899.2023.2173173","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction Dry eye disease is a prevalent, multifactorial disease characterized by loss of tear film homeostasis. A myriad of ocular therapeutics is commercially available and in development for personalized management of dry eyes. Recently, Varenicline solution nasal spray (VNS) received approval from the US Food and Drug Administration for the treatment of dry eyes. Areas covered This review explores the current mainstay treatments for dry eyes and the role of VNS in addressing unmet needs in the treatment of dry eye disease. A PubMed and MEDLINE keyword search on Tyrvaya and Varenicline nasal solution spray was performed as a part of the inclusion criteria. Varenicline solution nasal spray has been shown to be well tolerated and demonstrated to provide clinically significant improvement in patients with dry eyes Expert opinion Treatment of dry eye disease with VNS may be most beneficial in patients with limited upper-body mobility, dexterity issues, tremors, and glaucoma.","PeriodicalId":39989,"journal":{"name":"Expert Review of Ophthalmology","volume":"18 1","pages":"1 - 10"},"PeriodicalIF":0.9000,"publicationDate":"2023-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17469899.2023.2173173","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
ABSTRACT Introduction Dry eye disease is a prevalent, multifactorial disease characterized by loss of tear film homeostasis. A myriad of ocular therapeutics is commercially available and in development for personalized management of dry eyes. Recently, Varenicline solution nasal spray (VNS) received approval from the US Food and Drug Administration for the treatment of dry eyes. Areas covered This review explores the current mainstay treatments for dry eyes and the role of VNS in addressing unmet needs in the treatment of dry eye disease. A PubMed and MEDLINE keyword search on Tyrvaya and Varenicline nasal solution spray was performed as a part of the inclusion criteria. Varenicline solution nasal spray has been shown to be well tolerated and demonstrated to provide clinically significant improvement in patients with dry eyes Expert opinion Treatment of dry eye disease with VNS may be most beneficial in patients with limited upper-body mobility, dexterity issues, tremors, and glaucoma.
期刊介绍：
The worldwide problem of visual impairment is set to increase, as we are seeing increased longevity in developed countries. This will produce a crisis in vision care unless concerted action is taken. The substantial value that ophthalmic interventions confer to patients with eye diseases has led to intense research efforts in this area in recent years, with corresponding improvements in treatment, ophthalmic instrumentation and surgical techniques. As a result, the future for ophthalmology holds great promise as further exciting and innovative developments unfold.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
